Molecular Iodine Synergized And Sensitized Neuroblastoma Cells To The Antineoplastic Effect Of Atra

ENDOCRINE-RELATED CANCER(2020)

引用 2|浏览9
暂无评分
摘要
Neuroblastoma (NB) is the most common solid childhood tumor, and all-trans retinoic acid (ATRA) is used as a treatment to decrease minimal residual disease. Molecular iodine (I-2) induces differentiation and/or apoptosis in several neoplastic cells through activation of PPAR gamma nuclear receptors. Here, we analyzed whether the coadministration of I-2 and ATRA increases the efficacy of NB treatment. ATRA-sensitive (SH-SY5Y), partially-sensitive (SK-N-BE(2)), and non-sensitive (SK-N-AS) NB cells were used to analyze the effect of I-2 and ATRA in vitro and in xenografts (Foxn1 nu/nu mice), exploring actions on cellular viability, differentiation, and molecular responses. In the SH-SY5Y cells, 200 mu M I-2 caused a 100-fold (0.01 mu M) reduction in the antiproliferative dose of ATRA and promoted neurite extension and neural marker expression (tyrosine hydroxylase (TH) and tyrosine kinase receptor alpha (Trk-A)). In SK-N-AS, the I-2 supplement sensitized these cells to 0.1 mu M ATRA, increasing the ATRA-receptor (RAR alpha) and PPAR gamma, expression, and decreasing the Survivin expression. The I-2 supplement increased the mitochondrial membrane potential in SK-N-AS suggesting the participation of mitochondrial-mediated mechanisms involved in the sensibilization to ATRA. In vivo, oral I-2 supplementation (0.025%) synergized the antitumor effect of ATRA (1.5 mg/kg BW) and prevented side effects (body weight loss and diarrhea episodes). The immunohistochemical analysis showed that I-2 supplementation decreased the intratumoral vasculature (CD34). We suggest that the I-2 + ATRA combination should be studied in preclinical and clinical trials to evaluate its potential adjuvant effect in addition to conventional treatments.
更多
查看译文
关键词
molecular iodine, ATRA, neuroblastoma, mitochondria, xenografts
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要